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Methods/results: Mice	 that	were	put	on	a	custom-made	chow	diet	 supplemented	
with	 rivaroxaban	 (0.4	or	1.0	mg/g	diet)	or	dabigatran	etexilate	 (DE)	 (10	mg/g	diet)	
showed	 prolonged	 ex	 vivo	 coagulation	 times	 (prothrombin	 time	 [PT]	 and	 acti-
vated	 partial	 thromboplastin	 time	 [aPTT]	 assay,	 respectively).	 However,	 rivaroxa-
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1  | INTRODUC TION
Cancer	patients	have	a	seven-fold	increased	risk	for	venous	throm-
boembolism	 (VTE),1	 and	 this	 risk	 is	 dependent	 on	 treatment,	 pa-
tient-related	 factors,	 tumor	 type,	 and	 disease	 stage.2,3	 In	 patients	
receiving	 chemotherapy,	 it	was	demonstrated	 that	 thromboembo-




Over	 the	 years,	 low-molecular-weight	 heparins	 (LMWH)	 and	
vitamin	 K	 antagonists	 (VKAs)	 have	 shown	 to	 be	 effective	 antico-





and	 FAMOUS7,8)	 demonstrated	 that	 LMWH	 treatment	 resulted	
in	a	survival	benefit,	particularly	 in	patients	with	a	good	prognosis	










membrane	 of	 platelets,	 endothelial	 and	 perivascular	 cells,	 directly	
regulating	 adhesion,	migration	 and	 survival.11	 Increasing	 evidence	











cells when subcutaneously injected;24 nor did they inhibit metasta-
sis	formation	in	an	experimentally	induced	liver	metastasis	model.25 
Apart	 from	 their	 anticoagulant	 activity,	 LMWHs	possess	 a	 variety	
of	 biological	 activities	 that	 may	 explain	 the	 observed	 anticancer	
effects,	 including	 inhibition	of	heparanase,	blockade	of	P-selectin-
dependent	 and	 L-selectin-dependent	 cell	 adhesion,	 impairment	 of	





































is	 a	 multibarrier	 and	 specific-pathogen-free	 facility.	 The	 FELASA	
recommendations	for	the	health	monitoring	in	experimental	units39 
were	 used.	Mice	 were	 housed	 in	 Sealsafe®	 PLUS,	 green	 line	 sys-
tem	 (Tecniplast	 S.p.A.)	 autoclaved	GM500	 cages,	with	 autoclaved	
LIGNOCEL®	BK	8-15	 (BK-8-15-00433,	 JRS)	bedding	material.	The	
Essentials
•	 Factor	 Xa	 (FXa)-targeting	 direct	 oral	 anticoagulants	
(DOACs)	reduce	venous	thromboembolism	(VTE)
•	 The	effects	of	FXa-targeting	DOACs	on	cancer	progres-













weight,	 comparable	 groups	were	made	 and	 randomly	 allocated	 to	
the	 experimental	 treatments	 using	 a	 computer-generated	 random	
number.	After	measurements	 (see	2.2),	 cages	were	placed	back	 in	
random	order	in	the	rack	in	the	animal	room.	Mice	were	fed	regular	
chow-diet	 (RM3	diet,	pelleted,	 irradiated	9	kGy,	SDS	diets)	or	cus-
tom-made	 chow	diet	 (see	 the	 following)	 ad	 libitum.	Custom-made	
chow	diet	was	prepared	by	boiling	600	mL	tap	water	with	24	g	agar	
(Sigma-Aldrich),	adding	600	mL	sterile	aqua	dest,	and	subsequently	
mixing	 well	 with	 1200	 g	 diet	 powder	 (RMH-B,	 9	 kGy	 irradiated,	
ABDiets,	Woerden,	The	Netherlands).	Chow	diet	was	 freeze-dried	
for	at	least	3	days,	and	stored	at	−20°C	until	further	use.	For	the	spe-






2.2 | Orthotopic breast cancer models
The	 MDA-MB-231	 and	 MDA-MB-231-LC	 cells	 (see	 2.4)	 (1	 ×	 106 
in 50 μL	 PBS)	were	 injected	 into	 the	 fourth	mammary	 fat	 pad	 of	
female	 NOD-SCID	 or	 NSG	 mice	 (as	 described	 in	 detail	 in	 refer-
ence 40).	 HCC1806	 cells	 (2	 ×	 106	 in	 matrigel:PBS,	 1:1)	 were	 in-
jected	 into	 the	 fourth	 mammary	 fat	 pad	 of	 7-week-old	 female	









rived	 from	 American	 Type	 Culture	 Collection	 (ATCC,	 Manassas,	
VA).	 MDA-MB-231	 cells	 were	 cultured	 in	 DMEM	 1×	 (Dulbecco's	
Modified	 Eagle	Medium,	 4.5	 g/L	D-glucose,	 L-glutamin,	 pyruvate;	
ThermoFisher	 Scientific,	 Breda,	 The	 Netherlands)	 supplemented	
with	10%	fetal	bovine	serum	(FBS)	and	1%	penicillin	and	streptomy-
cin	 (pen-strep).	HCC1806	cells	were	cultured	in	RPMI1640	(L-argi-




2.4 | Generation of the MDA‐MB‐231 lung‐
metastatic clone
To	 generate	 GFP-positive	 cells,	 MDA-MB-231	 cells	 were	 stably	
transduced	 with	 the	 MISSION®	 pLKO.1-puro-CMV-TurboGFP™ 
plasmid	 (Sigma-Aldrich)	using	 the	2nd	generation	 lentiviral	pack-
aging	system,	using	psPAX2	and	pVSVG	vectors.	Forty-eight	hours	











The	 PT	 was	 determined	 by	 adding 33.7	 μL	 diluent	 (0.1%	 BSA	 in	
20	mmol/L	HEPES,	150	mmol/L	NaCl,	 0.1%	PEG-8000,	5	mmol/L	
CaCl2,	pH	7.5)	 to	a	16.3	μL	plasma	sample,	 followed	by	a	60-s	 in-






ent to a 12.5 μL	plasma	sample	and	mixed	with	25	μL	aPTT	reagent	








human	 FXa	 and	 Spectrozyme	 Fxa	 American	 Diagnostica	 Inc	
(Stamford,	 CT;	 now	 Sekisui	 Diagnostics)	 were	 added	 to	 reach	
a	 final	 concentration	 of	 5	 nmol/L	 and	 250	μmol/L,	 respectively.	
Factor	Xa	activity	was	subsequently	measured	by	using	a	kinetic	
recording	spectrophotometer.
2.6 | Ribonucleic acid, complementary 
deoxyribonucleic acid, and quantitative polymerase 
chain reaction
To	determine	gene	expression	(CXCL8,	VEGFA),	300	000	cells	were	
seeded	 per	 6-well	 in	 regular	 culture	 medium.	 The	 following	 day,	
the	 medium	 was	 aspirated	 and	 replaced	 by	 serum-free	 medium.	
After	 24	 h	 of	 serum	 starvation,	 cells	 were	 stimulated	 with	 FXa	
(Haematologic	 Technologies	 Inc.,	 Essex	 Junction,	VT)	 or	 thrombin	
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(Enzyme	Research	Laboratories,	South	Bend,	IN)	in	the	presence	or	
absence	 of	 rivaroxaban	 (Alsachim,	 Ilkirch	 Graffenstaden,	 France)	













2.7 | Proliferation, clonogenic, and sphere assays
The	 MTS	 proliferation	 assay	 was	 performed	 as	 described	 by	 the	
manufacturer's	 protocol	 (Promega,	 Leiden,	 The	 Netherlands).	 In	





plate	 in	 culture	 medium,	 and	 coagulation	 factors	 or	 vehicle	 was	
added	 the	 subsequent	 day.	 The	 number	 of	 colonies	 was	 counted	
manually	 7	 (MDA-MB-231)	 and	14	 (HCC1806)	 days	 later	 using	 an	
inverted	 laboratory	 microscope	 (Leica	 DM	 IL	 LED).	 In	 the	 mam-
mosphere	 assay,	 cells	were	 resuspended	 three	 times	 using	 a	 25G	
needle	 and	 100	 cells/96-well	 were	 seeded	 in	 a	 low-attachment	
plate	 in	 DMEM/F12	 phenol-red	 free	 medium	 supplemented	 with	
1×	B-27	 (minus	 vitamin	A,	ThermoFisher	 Scientific)	 and	20	ng/mL	
hEGF	 (ThermoFisher	Scientific).	Pictures	were	 taken	with	a	digital	
microscope	 camera	 (Leica	 DFC295)	 8	 days	 later.	 Mammospheres	
with	a	diameter	 larger	 than	50	μmol/L	 (using	 Image	 J	 for	analysis)	
were	counted,	and	mammosphere	forming	efficiency	is	shown	as	the	
number	of	mammospheres/cells	seeded.
2.8 | Live cell imaging‐based random 
cell migration assay
A	 live	 cell	 imaging-based	 random	 cell	 migration	 assay	 was	 per-
formed	 as	 previously	 described.41	 In	 short,	 10	 000	MDA-MB-231	
and	HCC1806	cells	were	seeded	in	medium	containing	10%	FBS	in	a	
96-well	in	200	μL.	The	next	day,	cells	were	incubated	with	Hoechst	




To	 allow	 for	 automated	 nuclear	 cell	 tracking	 the	 96-well	 plate	
was	placed	on	a	Nikon	Eclipse	TE2000-E	microscope	fitted	with	a	
37°C	 incubation	chamber,	20×	objective	 (0.75	NA,	1.00	WD),	and	












To	 study	 the	effects	of	DOACs	on	breast	 cancer	 growth	and	me-
tastasis,	we	 tested	 the	 effects	 of	 two	 types	 of	 clinically	 available	
DOACs,	 the	 FXa-targeting	 rivaroxaban	 and	 the	 thrombin-target-
ing	DE,	in	orthotopic	breast	cancer	models.	As	a	proof	of	principle,	
relatively	 high	 doses	 of	 rivaroxaban	 (0.4	mg/g	 chow	 diet)	 and	DE	
(10	mg/g	chow	diet)	were	mixed	in	custom-made	chow	diet,	which	










cer	 cells	 in	 lungs	 and	 livers,	 human-specific	GAPDH	primers	were	





GAPDH	 product	 was	 detected	 in	 lungs	 that	 were	 not	 inoculated	
with	cancer	cells	(Figure	S2).	The	lower	detection	limit	of	detecting	
human	cancer	cells	 in	mouse	 lungs	using	this	qPCR	assay	 is	there-
fore	at	 least	10	cancer	cells.	 In	NSG	mice,	 relatively	high	 levels	of	
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In	addition,	Dewan	and	coworkers	demonstrated	that	s.c.	 injected	







tested	 the	effects	of	 rivaroxaban	 treatment	on	 tumor	growth	and	
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*P <	0.05,	**P <	0.01,	***P <0.001	vs	respective	Vehicle;	NS,	not	significant.	aPTT,	activated	partial	thromboplastin	time;	PT,	prothrombin	
time;	qPCR,	quantitative	polymerase	chain	reaction
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Tukey's	multiple	comparison	test	was	performed	(A-H).	*P <	0.05,	**P <	0.01,	***P <	0.001	vs	Control,	#P <	0.05	vs	FXa,	##P <	0.01	vs	FXa,	






























































































































Control FIIa Dabi. FIIa+Dabi.







Control FXa Riva. FXa+Riva.
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Despite	 the	 induction	 of	 these	 downstream	 targets,	 FXa	 and	
thrombin	were	unable	to	 induce	migration	of	either	MDA-MB-231	
or	HCC1806	cells	in	a	live	cell	imaging-based	assay	in	the	presence	
of	 0%	 or	 10%	 FBS	 (Figure	 S5A,B).	 While	 MDA-MB-231	 cells	 did	
not	show	any	significant	response	to	FBS	exposure,	the	motility	of	
HCC1806	cells	was	significantly	enhanced	 in	the	presence	of	10%	
FBS	when	 compared	 to	 the	 0%	FBS	 condition.	However,	 addition	
of	either	FXa	or	thrombin	did	not	affect	the	migratory	behavior	of	
either	TNBC	cell	line,	even	in	serum-free	conditions.
Using	 an	MTS	 assay	 we	 observed	 that	 FXa	 and	 thrombin	 did	
not	 affect	 the	 number	 of	 viable	MDA-MB-231	 or	 HCC1806	 cells	
in	 the	 presence	 of	 either	 0%	 or	 10%	 FBS	 (Figure	 S6).	 To	 study	
potential	 effects	 of	 FXa	 and	 thromin	 on	 breast	 cancer	 stem	 cells,	
clonogenic	and	mammosphere	assays	were	performed.	Factor	Xa	did	
not	affect	clonogenicity	of	either	MDA-MB-231	or	HCC1806	cells	










Cancer	patients	with	VTE,	or	at	high	 risk	 for	VTE,	 receive	 routine	
thromboprophylaxis.	 In	 preclinical	 cancer	 models,	 the	 clinically	




VTE	 recurrence	 effectively	 in	 patients	 without	 cancer.	 Recently,	
FXa-targeting	DOACs	(edoxaban	and	rivaroxaban)	also	reduced	VTE	
recurrence	in	cancer	patients.36,37	To	date,	the	potential	anticancer	
effects	 of	 FXa-targeting	DOACs	 have	 not	 been	 addressed	 in	 pre-
clinical cancer models.
In	 this	 study,	we	 have	 shown	 that	 both	 a	 FXa-targeting	 and	 a	




would	have	 inhibited	metastasis	 formation	 in	an	experimental	me-









that	 the	 orthotopic	model	 used	 is	 clinically	more	 relevant	 and	we	
therefore	refrained	from	using	the	experimental	metastasis	model.
In	 contrast	 to	 FXa-targeting	DOACs,	 a	 few	 studies	 have	 ad-
dressed	the	role	of	thrombin-targeting	DOACs	in	preclinical	can-
cer	models.	 In	 an	 orthotopic	model	 using	 breast	 cancer	 cells	 of	
murine	 origin,	 DeFeo	 et	 al	 showed	 that	 DE	 treatment	 -	 started	
1	 day	 before	 orthotopic	 inoculation	 of	 cancer	 cells	 -	 inhibited	
cancer	 growth	 at	 primary	 and	metastatic	 sites.49	 Tumor	 growth	
was	 not	 affected	when	DE	 treatment	was	 started	16	days	 after	
orthotopic	 inoculation	 of	 breast	 cancer	 cells,	 but	 DE	 treatment	
potentiated	 the	antitumor	effects	of	 the	chemotherapeutic	drug	
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cyclophosphamide	in	this	setting,	via	reducing	the	number	of	TF-
positive	 microparticles	 and	 decreasing	 the	 number	 of	 activated	
platelets.50	A	different	picture	emerged	in	a	xenograft	model	using	
pancreatic	cells	of	human	origin,	where	DE	did	not	affect	cancer	
growth	 or	 metastasis,	 but	 increased	 CD31+	 vessel	 density	 and	
proliferation,	 potentiating	 the	 effects	 of	 the	 chemotherapeutic	
drug	gemcitabine.51
In	 line	with	 the	 current	 notion	 in	 literature	 that	 NK	 cells	 play	






not	have	a	 full	 immune	competent	system.	On	the	other	side,	 this	
allowed	us	to	study	effects	of	anticoagulants	on	clinically	more	rele-
vant human cancer cells.






target	 for	 an	 anticoagulation	 treatment.	 Moreover,	 thrombin	 also	
serves	 as	 a	 potent	 platelet	 agonist	 resulting	 in	 activated	 platelets	
that	augment	 thrombin	generation,	whereas	FXa	has	no	effect	on	
platelet	activation.55
In	 the	coagulation	cascade,	 the	 intrinsic	 and	extrinsic	pathway	
converge	 at	 FX	 activation,	 where	 one	molecule	 of	 FXa	 results	 in	
the	generation	of	1000	molecules	of	thrombin.56	Therefore,	it	may	




has	 superior	 antithrombotic	 potential	 and	 safety	 compared	 to	 the	
LMWH	 enoxaparin,	 which	 exerts	 both	 anti-Xa	 and	 antithrombin	
activity.59
Besides	effects	on	coagulation,	thrombin	can	also	activate	PAR1-
signaling	 in	 cancer	 cells	 and	platelets,	 exerting	 a	variety	 of	 protum-
origenic	effects	including	induction	of	migration,	invasion,	cancer	cell	
adhesion,	 and	 induction	 of	 metastatic	 potential	 in	 an	 experimental	




protein	kinase	B,	and	mTOR	pathway,14,62 others demonstrated that 
FXa	inhibited	migration	via	PAR1-mediated	Rho/ROCK	and	Src/FAK/
paxillin-signalling	in	breast	cancer	cells.63
In	 the	absence	of	 randomized	clinical	 trials,	 a	network	meta-
analysis	 was	 conducted	 to	 compare	 the	 efficacy	 and	 safety	 of	
the	 DOACs	 rivaroxaban,	 apixaban,	 edoxaban,	 and	 dabigatran	 in	
the	 treatment	 of	 VTE.31	 All	 DOACs	 showed	 statistically	 similar	
reductions	 in	the	risk	of	VTE	or	VTE-related	death.	A	significant	
reduction	 in	number	of	bleedings	was	established	with	apixaban	
compared	with	 all	 other	DOACs,	 and	with	 dabigatran	 compared	
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